NCT05711719View on ClinicalTrials.gov

Vericiguat in Patients With Metabolic Syndrome and Coronary Vascular Dysfunction

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 16, 2023

Primary Completion Date

November 16, 2025

Study Completion Date

April 30, 2026

Conditions
Metabolic SyndromeCoronary Microvascular Dysfunction
Interventions
DRUG

Vericiguat

Up-titration will be performed as guided by the evaluation of blood pressure and clinical symptoms

DRUG

Placebo

Administered the same way

Trial Locations (1)

21287

RECRUITING

Johns Hopkins Hospital, Baltimore

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Johns Hopkins University

OTHER